As­traZeneca's Farx­i­ga scores FDA nod to cut risk of hos­pi­tal­iza­tion for heart fail­ure in di­a­bet­ics

While the FDA re­cent­ly spurned an ap­pli­ca­tion to al­low As­traZeneca’s block­buster drug Farx­i­ga for type 1 di­a­betes that can­not be con­trolled by in­sulin, cit­ing safe­ty con­cerns — the US reg­u­la­tor has en­dorsed the use of the SGLT2 treat­ment to re­duce the risk of hos­pi­tal­i­sa­tion for heart fail­ure in pa­tients with type-2 di­a­betes and es­tab­lished car­dio­vas­cu­lar dis­ease or mul­ti­ple CV risk fac­tors.

Farx­i­ga is the first SGLT2 in the Unit­ed States to se­cure ap­proval in this pa­tient pop­u­la­tion, As­traZeneca in­di­cat­ed on Mon­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.